Integer (US:ITGR) ZACKSยท2025-10-24 18:55Core Insights - Integer Holdings Corporation (ITGR) reported adjusted earnings per share (EPS) of $1.79 for Q3 2025, reflecting a year-over-year increase of 25.2% and exceeding the Zacks Consensus Estimate by 6.6% [1][9] - The company generated revenues of $467.7 million in Q3 2025, marking an 8.4% increase year over year and surpassing the Zacks Consensus Estimate by 0.4% [2][9] - Despite strong quarterly results, ITGR shares fell over 30% due to concerns regarding slower revenue growth guidance for 2026 [9][13] Revenue Breakdown - Revenues from the Cardio and Vascular (C&V) segment reached $277.1 million, up 14.9% year over year, driven by new product ramps and strong customer demand [5] - The Cardiac Rhythm Management & Neuromodulation (CRM&N) segment reported revenues of $169.2 million, reflecting a 2.5% year-over-year increase [6] - Other Markets revenues totaled $21.4 million, down 15.5% year over year, attributed to the planned exit from Portable Medical [7] Margin and Expense Analysis - Gross profit for Q3 2025 was $126.2 million, an 8.2% increase year over year, with a gross margin of 26.9%, a slight contraction of 10 basis points [8][10] - Selling, general and administrative expenses rose to $50.5 million, up 12.6% year over year, while research and development costs decreased to $10.9 million, down 8.2% [10] Financial Position - At the end of Q3 2025, Integer Holdings had cash and cash equivalents of $58.9 million, up from $23.1 million at the end of Q2 2025, with total debt decreasing to $1.19 billion [11] 2025 Guidance - The company updated its 2025 revenue guidance to a range of $1,840 million to $1,854 million, indicating a 7-8% improvement from 2024, while adjusted EPS is expected to be between $6.29 and $6.43, reflecting a 19-21% increase [12]